Mysterious ‘ship goo' contains new life forms
The muck looked like thick grease or oil, Ricketts tells Popular Science, but the rudder shaft wasn't supposed to be lubricated by anything more than lake water. Instead of a strong petroleum odor, the goop had a metallic smell. It also didn't leave a sheen on water, nor burn up in a blowtorch flame, during informal tests conducted by Blue Heron Captain Rual Lee. So, what was it?
On the quest for answers, Ricketts brought a paper coffee cup half-filled with the mystery goop (labeled 'ship goo' in haphazard marker strokes) to university scientists. Laboratory analysis has prompted more questions than clarity, but the initial assessment of the 'ship goo' yielded at least one startling discovery. The mysterious tar-like material contained previously unidentified forms of life.
'I really didn't think we'd get anything, to be honest,' Cody Sheik, a microbial ecologist at the University of Minnesota Duluth tells Popular Science. 'Usually, when you're given a cup of tar,' you don't expect much, he adds. Under that assumption, he 'handed it off to a graduate student and said 'good luck'.'
The graduate student successfully extracted DNA from the goo, defying Sheik's initial expectations– but still, he thought it might be routine sample contamination. It was only after the lab sent the extracted DNA off for preliminary, single-gene sequencing that Sheik realized he was in uncharted territory. When the results came back, he was shocked. 'A lot of the sequences came out really novel. I was like, 'oh, oh no, okay– this is a whole different story',' he says.
[ Related: Pollution-eating microbes are thriving in infamous NYC canal. ]
For a deeper look into the goo's microbial makeup, Sheik and his colleagues sent the sample for a second round of sequencing. This time, they examined the whole genomes inside of the goo, instead of just a single key gene region. The analysis confirmed that, though the goop microbes weren't especially diverse, they were unique. They reconstructed the genomes of more than 20 microbes, and compared them to comprehensive databases of previously identified organisms. According to Sheik, they found several novel archaea– members of a domain of single-celled, prokaryotic life that are distinguished from bacteria by their cell membrane composition.
One of the microbes they found represents, not just a new species, but an entirely new order of archaea. For now, the scientists are officially referring to it as ShipGoo01. Another promising, oddball microbe could be a whole new bacterial phylum, Sheik says. If confirmed, that would probably be christened ShipGoo002. Others, too, might prove new to science. 'There's several of them that may be new genus, may be new families, for sure,' he notes.
ShipGoo01 seems to be anaerobic, meaning it prefers an oxygen-free environment. Other microbes in the goo seem to gobble oxygen up and Sheik suggests that it's possible these exist in a mutually beneficial balance.
Of the more familiar microbes and genetic markers, database comparison indicates that the bulk of the teeny tiny organisms are similar to those associated with oil wells, tar pits, and other hydrocarbon systems. Several seem to be related to microorganisms with international origins– from places like Germany. 'That's been kind of fun– trying to figure out where [it's from] and why it's in the rudder system here. It's becoming quite baffling,' Sheik says. In part, again, because the Blue Heron's rudder isn't regularly greased with oil, and because it sails on the Great Lakes in the Midwest.
The ship hasn't always been in University of Minnesota custody. It was purchased pre-owned in 1997, Ricketts says, so it's entirely possible that the prior owners of the vessel did apply some sort of petroleum-based lubricant to the rudder shaft. But generally microbes need a steady food supply. Without any additional influx of grease in over 25 years, it's hard to know what the oil-associated microbes might be eating after all this time.
Perhaps they're subsisting off of the metal itself, though Ricketts notes that the rudder shaft didn't look particularly damaged. Maybe organic matter from the lake water feeds the micro-beasts. Or maybe some secret third thing is going on.
'The more we start getting into this, the more I'm kind of clueless here,' Sheik says. 'We're doing a lot of sleuthing to try to figure this thing out.'
He's hoping to get better answers on what the microbes are floating around in, and all of the microbial metabolic pathways present in the goop. Sheik also imagines using chemical isotope analysis down the line to establish where the atoms in the system are coming from. The carbon and nitrogen in algae, for instance, have a very different profile from the equivalent molecules in motor lube. 'It's like a 1,000 piece puzzle that we're trying to put together,' without any picture on the box to go off of, Sheik says. Once more of the image becomes clear, his lab plans to publish their findings in a peer-reviewed scientific journal.
[Related: Can microbes that devour plastic waste be transformed into food for humans?]
But there's one big challenge the scientists might not be able to overcome. The cup of goo (comprising about 100 milliliters of gunk) was the only sample taken, and getting more could be difficult–nigh impossible. The ship would have to be put in dry dock, with the rudder, once again, disassembled. And 'unfortunately, they did a really good job cleaning it last time before they put it back,' Sheik says. The rest of the ship goo 'may be lost forever.'
Or maybe not. 'I don't think this ship is unique. I really strongly suspect that if you took the rudder post of any ship anywhere, there's a possibility of finding some organism–maybe a new organism–in that space,' Ricketts says.
Before this, it would've been easy for him to imagine strange microorganisms popping up in a ship galley or on a fuel filter. But of all the places for something like this to be found, the mechanical rudder shaft at the far end of a ship is among the weirdest, Ricketts says. It just goes to prove, 'microbes are everywhere.'
To better understand more of those undiscovered lifeforms, hiding in plain sight, Sheik says his lab would need secure funding and resources. Like many university science labs that rely, in large part, on taxpayer dollars, the future of his work is up in the air.
'Right now we're in this weird spot where we're just trying to struggle to keep our labs open,' he says. He worries that, moving forward, we'll miss out on ShipGoo3– but also on all the would-be advances that might come from it.
Many prior microbe discoveries have proved useful in fields as varied as waste management and pollution remediation to life-saving drug development. 'As these dollars go away, our ability to do this primary research that can drive innovation goes away and could be lost for a very long time.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
2 days ago
- Forbes
Why All Eyes Should Be On Manchester When It Comes To Regional Innovation
The UK's innovation and industrial agendas have historically been shaped by successive Westminster Governments, often leaving the insight and contribution of some of the UK's regional powerhouses behind. The recent announcement that the Industrial Strategy Council will be headquartered in Manchester, however, signals a much-needed shift away from centralised control, to one that recognises the incredible industrial heritage of the regions and the innovation being driven across the UK today. Manchester has created the blueprint for regional innovation, one grounded in long-term collaboration. It's a model that other areas across the UK would do well to study and adopt. This approach has not only elevated Manchester's profile but also attracted significant national and international attention and investment. Crucially, the city isn't standing still. The Greater Manchester Combined Authority (GMCA) recently announced The Greater Manchester Strategy, a ten-year vision underpinned by seven delivery workstreams that will cement Greater Manchester as 'a thriving city region where everyone can live a good life'. This new plan builds on Manchester's proven formula and introduces seven delivery workstreams designed to strengthen integration of public, private and academic sector ecosystems, and investment in growth areas and R&D. On the topic of which, recently we've seen a rapid growth in AI with Manchester and Salford ranked top for AI-readiness outside of London. The city is also leading the charge in digital health, data infrastructure, cybersecurity and FinTech businesses – all of which also align with the new Industrial Strategy's pillars – and it's becoming common knowledge that Manchester has earned a reputation as a world-class hub for life sciences in recent years. Indeed, Manchester's Inward Investment Agency, MIDAS, recently launched a new life sciences prospectus showcasing the city region's position as one of the UK's most dynamic health innovation ecosystems. Produced by MIDAS and the Oxford Road Corridor – Manchester's knowledge quarter – with contributions from a collection of key regional stakeholders including Bruntwood SciTech - the prospectus highlights the city's position within the UK's £120bn growing life sciences market and showcases its regional strengths in data, genomics, oncology and real-world evidence clinical trials. Rather than a city playing catch up, Manchester is a city setting the pace. But what truly sets it apart isn't just the funding it's received or the institutions it hosts, it's that the city has never waited for permission. Build first, attract later Manchester's progress and success has been the result of decades-long collaboration and a united long-term vision between civic leaders, universities, property developers and industry, forming an innovation ecosystem that existed well before national attention followed. Take Manchester Science Park with our new Greenheys development at its heart. The site is set to become home to UK Biobank, the world's most significant source of data and biological samples for health research. UK Biobank being a part of Manchester's already thriving ecosystem has been instrumental in securing the £20 million being awarded through the Industrial Strategy, supporting its delivery of the world's most significant protein study. With the data made accessible to approved researchers worldwide, the project exemplifies how locally driven success stories can attract major government backing and deliver global scientific value. The timing is also significant. The NHS's new 10-year plan announced at the beginning of July places renewed emphasis on data-driven innovation, early diagnostics and partnership with industry. In Manchester, we're already seeing how strong relationships between Manchester University NHS Foundation Trust, the Oxford Road Corridor and joint ventures like Bruntwood SciTech can deliver on this vision. The co-location of life science businesses alongside NHS clinicians and researchers offers a powerful draw for tech, innovation and science businesses looking to scale in a real-world healthcare setting. By demonstrating ambition, clarity and joined up thinking locally, Manchester has built something that national government is now backing. Local leadership, national returns Manchester may be the blueprint, but cities like Liverpool, Leeds, Birmingham and Glasgow are also carving distinct innovation paths that deserve greater attention and resourcing. Liverpool is expanding its Knowledge Quarter with a growing focus on infection research and digital health, powered by strong university partnerships and the proactive work of local leaders to create a globally recognised health and life sciences cluster. Meanwhile, Leeds has become a centre of excellence in med tech, Glasgow is establishing itself as a leader in quantum and photonics, and Birmingham is capitalising on its strengths in clean tech and advanced manufacturing, with innovation campuses like Tyseley Energy Park and Birmingham Health Innovation Campus. In each case, we see the same pattern: regional stakeholders identifying their unique assets, building coalitions across academia, industry and public services, and developing the spaces, strategies and talent pipelines to match. This groundwork doesn't wait for central government support, it earns it. If the UK wants to truly unlock the power of regional innovation, it must move beyond one-off funding packages and lean into long-term partnerships with local authorities, councils, metro mayors and institutions that have proven they can deliver. The takeaway then isn't that Manchester is better – it's that it was prepared. The city offers a case study in how others can align infrastructure, leadership and industry to create self-sustaining innovation economies. And when this is done well, it doesn't just lead to local success, it attracts national investment.
Yahoo
2 days ago
- Yahoo
AstraZeneca announces $50bn US investment plans by 2030
AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). The investment represents a substantial capital infusion to the $3.5bn announced in November 2024. The focus of this investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca's weight management and metabolic product range. This portfolio includes oral glucagon-like peptide-1 (GLP-1), baxdrostat, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) and combination small molecule treatments. The new facility will be designed to manufacture peptides, small molecules and oligonucleotides. To be constructed in the Commonwealth of Virginia, the plant will be AstraZeneca's single manufacturing venture globally. The new facility will incorporate advanced technologies such as AI, automation and data analytics to enhance production capabilities. This financial commitment will generate new direct and indirect jobs in the US. AstraZeneca CEO Pascal Soriot stated: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80bn in revenue by 2030.' The investment also covers other projects: the expansion of AstraZeneca's R&D facility in Gaithersburg, Maryland, and the establishment of an advanced R&D centre in Kendall Square, Cambridge, Massachusetts. The company will also develop next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California, as well as expand its continuous manufacturing operations in Mount Vernon, Indiana. The investment encompasses the expansion of speciality manufacturing in Coppell, Texas, the establishment of new sites to support clinical trials, and an increase in funding for research and development of new medicines. In July 2025, Modella AI entered a multi-year partnership with AstraZeneca aimed at accelerating AI-driven clinical development in oncology. "AstraZeneca announces $50bn US investment plans by 2030" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing
Video Link: UDAIPUR, India, July 21, 2025 /CNW/ -- Macsen Labs, a manufacturer of APIs, dyes, and specialty chemicals since 1952, has announced a major breakthrough in Sodium-Ion battery technology through the successful R&D-scale synthesis of its high-performance Prussian White, a next-generation cathode material for Sodium-Ion batteries. The company has filed a provisional patent for its proprietary synthesis process. The material has already undergone optimization for battery use at the company's electrochemistry and battery R&D facility and has shown promising results, driving the next phase toward pilot-scale manufacturing. "It's an interesting story, how a pharmaceutical company like ours entered the energy storage space," said Mr. Achal Agrawal, CEO of Macsen Labs and the lead researcher behind the project. "While working on Prussian Blue as a drug for radioactive poisoning, we discovered its derivative — Prussian White, which was emerging as a leading candidate for Sodium-Ion battery cathodes. That moment of curiosity led us down this path." Exactly one year ago, with zero experience in electrochemistry, Macsen's team fabricated a basic pouch cell inside a regular chemistry R&D lab, without specialized equipment. "We had no glovebox, no coater, no calendering machine, just our lab experience and synthesized material," recalled Agrawal. "When that small cell lit up an LED bulb, we knew we had something worth pursuing. That spark led us to establish a full-fledged electrochemistry lab." Today, Macsen's battery R&D facility includes an argon-filled glovebox for inert atmosphere handling, coin and pouch cell fabrication stations, electrode coaters, crimpers, vacuum dryers, and electrochemical testing systems, such as cyclers and potentiostats. With this setup, Macsen can rapidly prototype and test battery cells using its own synthesized materials, significantly reducing development time. The company already operates a pilot-scale chemical synthesis facility, which is now being used to produce Prussian White at a kilogram scale. Through numerous experiments conducted over the last year, the team has gained proficiency in Prussian White chemistry and has achieved what is likely to be one of the finest quality variants produced to date. Through its proprietary process, Macsen has achieved an energy density exceeding 150 mAh/g with Prussian White, which is comparable to Lithium Iron Phosphate (LFP). The material also shows excellent stability, fast sodium-ion mobility due to its open crystalline structure, and compatibility with existing Li-ion cell manufacturing infrastructure. "Performance-wise, it's at par with LFP, but made from abundant, low-cost materials like sodium and iron," said Agrawal. "And these elements are easily available, affordable, and free from geopolitical constraints." This project, originally incubated within Macsen Labs, is now being advanced under a dedicated entity currently under formation — 'Macsen Energy', which will focus exclusively on energy storage innovation and scale-up. "The real potential of sodium-ion batteries lies not just in electric vehicles," said Agrawal. "It lies in stationary energy storage systems that store and manage renewable energy from solar and wind. This is where India's energy transition will happen at scale." Macsen's current Sodium-Ion battery technology, using its Prussian White as cathode paired with a hard carbon anode, is well suited for applications such as battery energy storage systems (BESS) for grid and solar, household backup and inverter systems, short-range EVs, auto-rickshaws, two-wheelers, city buses, rural microgrids, and energy access solutions. The company is now focusing not only on improving cycle life, energy density, charge-discharge rates, and optimizing electrolyte-additive systems, but also on reducing the cost contribution of other components of the battery cell. Macsen aims to develop economical form factors by innovatively combining low-cost battery materials, components, and manufacturing processes, especially for large-scale stationary energy storage. One inherent cost advantage of sodium-ion technology is its use of aluminium in place of copper as the cathode current collector, which would further reduce raw material costs. To demonstrate the performance of Prussian White in commercial large-format cells, Macsen is setting up a pilot-scale cell fabrication line. The company is already sourcing equipment for this and aims to have the pilot-scale production facility operational by early 2026. "We are trying to make a new energy future for India," concluded Agrawal. "Sodium-ion batteries are India's opportunity to build a truly indigenous, scalable, and affordable energy storage ecosystem." Contactcorporate@ Video: View original content to download multimedia: SOURCE Macsen Labs Group View original content to download multimedia: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data